Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
2(20%)
Results Posted
117%(7 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
1
10%
Ph phase_1
6
60%
Ph phase_2
3
30%

Phase Distribution

6

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (60.0%)
Phase 23 (30.0%)
Phase 31 (10.0%)

Trials by Status

terminated220%
recruiting220%
completed660%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_1

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

NCT06516887
recruitingphase_3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

NCT07445048
terminatedphase_1

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

NCT05469178
completedphase_2

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03184571
completedphase_1

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT02424617
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06516887Phase 1

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting
NCT07445048Phase 3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Recruiting
NCT05469178Phase 1

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Terminated
NCT03184571Phase 2

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed
NCT02424617Phase 1

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Completed
NCT06469138Phase 1

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

Completed
NCT02488408Phase 1

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Completed
NCT04890509Phase 2

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

Completed
NCT03649321Phase 1

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Terminated
NCT03824080Phase 2

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10